vs
Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and DYNAVAX TECHNOLOGIES CORP (DVAX). Click either name above to swap in a different company.
CARRIAGE SERVICES INC is the larger business by last-quarter revenue ($105.5M vs $94.9M, roughly 1.1× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 11.6%, a 16.7% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 8.0%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $6.2M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 1.0%).
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
CSV vs DVAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $94.9M |
| Net Profit | $12.3M | $26.9M |
| Gross Margin | 34.8% | — |
| Operating Margin | 23.3% | 22.4% |
| Net Margin | 11.6% | 28.4% |
| Revenue YoY | 8.0% | 17.7% |
| Net Profit YoY | 24.5% | 53.0% |
| EPS (diluted) | $0.76 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.5M | — | ||
| Q3 25 | $102.7M | $94.9M | ||
| Q2 25 | $102.1M | $95.4M | ||
| Q1 25 | $107.1M | $68.2M | ||
| Q4 24 | $97.7M | $72.0M | ||
| Q3 24 | $100.7M | $80.6M | ||
| Q2 24 | $102.3M | $73.8M | ||
| Q1 24 | $103.5M | $50.8M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $26.9M | ||
| Q2 25 | $11.7M | $18.7M | ||
| Q1 25 | $20.9M | $-96.1M | ||
| Q4 24 | $9.9M | $7.0M | ||
| Q3 24 | $9.9M | $17.6M | ||
| Q2 24 | $6.3M | $11.4M | ||
| Q1 24 | $7.0M | $-8.7M |
| Q4 25 | 34.8% | — | ||
| Q3 25 | 35.3% | — | ||
| Q2 25 | 35.2% | — | ||
| Q1 25 | 35.3% | — | ||
| Q4 24 | 34.4% | — | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | 36.2% | — | ||
| Q1 24 | 36.0% | — |
| Q4 25 | 23.3% | — | ||
| Q3 25 | 17.0% | 22.4% | ||
| Q2 25 | 23.5% | 15.1% | ||
| Q1 25 | 29.5% | -34.7% | ||
| Q4 24 | 21.6% | -2.3% | ||
| Q3 24 | 22.7% | 12.5% | ||
| Q2 24 | 18.0% | 7.0% | ||
| Q1 24 | 18.8% | -35.0% |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | 28.4% | ||
| Q2 25 | 11.5% | 19.6% | ||
| Q1 25 | 19.5% | -141.0% | ||
| Q4 24 | 10.1% | 9.8% | ||
| Q3 24 | 9.8% | 21.8% | ||
| Q2 24 | 6.1% | 15.4% | ||
| Q1 24 | 6.7% | -17.2% |
| Q4 25 | $0.76 | — | ||
| Q3 25 | $0.41 | $0.21 | ||
| Q2 25 | $0.74 | $0.14 | ||
| Q1 25 | $1.34 | $-0.77 | ||
| Q4 24 | $0.62 | $0.07 | ||
| Q3 24 | $0.63 | $0.12 | ||
| Q2 24 | $0.40 | $0.08 | ||
| Q1 24 | $0.45 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $160.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.8M | $534.1M |
| Total Assets | $1.3B | $946.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | — | ||
| Q3 25 | $1.2M | $160.2M | ||
| Q2 25 | $1.4M | $99.1M | ||
| Q1 25 | $4.6M | $51.7M | ||
| Q4 24 | $1.2M | $95.9M | ||
| Q3 24 | $1.3M | $119.3M | ||
| Q2 24 | $1.5M | $112.5M | ||
| Q1 24 | $1.7M | $132.0M |
| Q4 25 | $254.8M | — | ||
| Q3 25 | $242.1M | $534.1M | ||
| Q2 25 | $235.4M | $494.2M | ||
| Q1 25 | $223.1M | $530.9M | ||
| Q4 24 | $208.6M | $596.8M | ||
| Q3 24 | $198.1M | $681.4M | ||
| Q2 24 | $187.9M | $642.8M | ||
| Q1 24 | $179.6M | $618.5M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $946.5M | ||
| Q2 25 | $1.3B | $918.4M | ||
| Q1 25 | $1.3B | $945.9M | ||
| Q4 24 | $1.3B | $986.3M | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.3B | $1.0B | ||
| Q1 24 | $1.3B | $986.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | $33.8M |
| Free Cash FlowOCF − Capex | $6.2M | $32.6M |
| FCF MarginFCF / Revenue | 5.9% | 34.4% |
| Capex IntensityCapex / Revenue | 7.5% | 1.3% |
| Cash ConversionOCF / Net Profit | 1.15× | 1.26× |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $80.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.1M | — | ||
| Q3 25 | $24.7M | $33.8M | ||
| Q2 25 | $8.1M | $23.4M | ||
| Q1 25 | $13.8M | $-19.6M | ||
| Q4 24 | $9.3M | $53.0M | ||
| Q3 24 | $20.9M | $19.5M | ||
| Q2 24 | $2.2M | $10.7M | ||
| Q1 24 | $19.7M | $-16.7M |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $18.0M | $32.6M | ||
| Q2 25 | $5.2M | $22.0M | ||
| Q1 25 | $10.6M | $-23.6M | ||
| Q4 24 | $4.9M | $49.5M | ||
| Q3 24 | $16.2M | $18.1M | ||
| Q2 24 | $-1.4M | $9.9M | ||
| Q1 24 | $16.2M | $-17.4M |
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.5% | 34.4% | ||
| Q2 25 | 5.1% | 23.0% | ||
| Q1 25 | 9.9% | -34.6% | ||
| Q4 24 | 5.0% | 68.8% | ||
| Q3 24 | 16.1% | 22.5% | ||
| Q2 24 | -1.4% | 13.5% | ||
| Q1 24 | 15.6% | -34.3% |
| Q4 25 | 7.5% | — | ||
| Q3 25 | 6.5% | 1.3% | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 3.0% | 5.8% | ||
| Q4 24 | 4.5% | 4.8% | ||
| Q3 24 | 4.6% | 1.7% | ||
| Q2 24 | 3.5% | 1.1% | ||
| Q1 24 | 3.4% | 1.5% |
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | 1.26× | ||
| Q2 25 | 0.69× | 1.25× | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.94× | 7.52× | ||
| Q3 24 | 2.11× | 1.11× | ||
| Q2 24 | 0.34× | 0.94× | ||
| Q1 24 | 2.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
